2021-05-21 08:40
Xintela meddelar idag att bolaget har erhållit tillstånd från Läkemedelsverket att producera cellterapiprodukter, så kallade avancerade terapiläkemedel (ATMPs), i den egna GMP-anläggningen.
2021-05-21 08:40
Xintela announces today that the company has received permission from the Medical Products Agency to produce cell therapy products, so-called advanced therapy drugs (ATMPs), in its own GMP facility.
2021-05-20 11:40
Xintela tillkännager idag att bolaget ska utveckla sin stamcellsprodukt XSTEM® för behandling av svårläkta (kroniska) sår. I samarbete med Brännskadecentrum vid Universitetssjukhuset i Linköping har Xintela i en preklinisk sårmodell visat utmärkt sårläkningsförmåga med XSTEM och planerar nu för en klinisk studie på patienter med svårläkta sår.
Wise Group (WISE:SS), the Swedish staffing firm, announced that it is offering the shareholders in Wise to acquire units, consisting of shares and warrants, in its subsidiary Brilliant Future.
Embracer Group completes the acquisitions of Aspyr, Easybrain and Gearbox Entertainment
STOCKHOLM, April 6, 2021 /PRNewswire/
On February 3, 2021 Embracer Group AB (the Company or Embracer Group ) and its subsidiaries entered into agreements regarding the acquisition of Aspyr, Easybrain and Gearbox Entertainment, which was announced through press releases on February 3, 2021 (the Transactions ). The aggregated day one purchase price for the Transactions amounts to approximately SEK 9.3 billion in total, on a cash and debt free basis. Approximately SEK 2.5 billion is paid in cash and approximately SEK 6.8 billion is paid in newly issued B shares of the Company. A maximum additional consideration amounting to SEK 12.5 billion on an aggregated basis can be paid, subject to fulfilment of agreed financial and operational milestones, during a period of up to 7 years. The additional consideration comprises a maximum of approximately SEK 7.0 billion to be paid in cash and approximat
Sivers Semiconductors Continues To Grow Number Of Design Wins
Sivers Semiconductors AB today announces that the company has won new design wins with three new customers. The aim is to use Sivers Semiconductors’ technology in new products in new verticals/for new use cases as well as in products at customers with an existing product line in the millimeter wave area.
Sivers Wireless has previously communicated 21 design wins where customers have existing agreements or have ongoing design and development activities integrating Sivers Wireless RFICs or RF Modules into their products. Now, the number of design wins are 24.
The first of these three design wins is with a European listed technology company with approx. 8 billion SEK in yearly net sales, who will base their upcoming technology platform and service offering on Sivers Wireless 5G millimeter wave product, the TRX BF/02. This engagement may present future volume opportunities over time, but at this point in time it is uncert
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma
Allarity Therapeutics A/SMarch 9, 2021 GMT
- Treatment of animal osteosarcoma models with dovitinib increased the median survival time by 50 % as compared to control animals.
Press release
Hørsholm, Denmark (9 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive data from its preclinical assessment of dovitinib’s antitumor activity in osteosarcoma, the most common primary malignant bone tumor in children and young adults. The purpose of the study was to investigate the capacity of dovitinib alone, and in combination with a specific checkpoint inhibition strategy (anti-PD-1), for slowing the progression of experimental pulmonary metastases in animal models of osteosarcoma.